

Special Issue

The Recent Trends in Oncologic Imaging

Message from the Guest Editors

This Special Issue entitled “The Recent Trends in Oncologic Imaging” will focus on novel and promising diagnostic tools for cancer imaging. Diagnostic imaging influences every step of oncologic patients, from diagnosis and treatment planning to response assessment to treatment and prognosis. In the era of precision medicine and personalized therapy, radiomics is promising to provide biological information of tumors on the basis of the inter-pixel relationship; these imaging biomarkers could be used for the purpose of diagnosis, prediction and assessment of treatment response, before conventional response assessment methods. Based on these premises, we invite authors to submit original researches and review articles on these fields of medical imaging applied to both solid and haematological malignancies.

- functional MRI
- perfusion MRI
- dual-energy CT
- perfusion CT
- positron emission tomography (PET)
- radiomics and AI applied to different imaging modalities

Guest Editors

Prof. Dr. Maria Antonietta Mazzei

Department of Medical, Surgical and Neuro Sciences, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy

Dr. Francesco Gentili

Unit of Diagnostic Imaging, Department of Radiological Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy

Dr. Alfonso Cerase

Azienda Ospedaliera Universitaria Senese, Siena, Italy

Deadline for manuscript submissions

closed (31 October 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106076

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).